Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke

NCT06648304 is registered in ClinicalTrials.gov with Shanghai Auzone Biological Technology Co., Ltd. as lead sponsor.

NCT NCT06648304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06648304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke
Lead sponsor
Shanghai Auzone Biological Technology Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 25, 2023
Completion date
June 17, 2024
Enrollment
614 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke